Back to Search
Start Over
Prolonged remissions after anti-PD1 discontinuation in patients with Hodgkin lymphoma
- Source :
- Blood, Blood, American Society of Hematology, 2018, 131 (25), pp.2856-2859. ⟨10.1182/blood-2018-03-841262⟩, Blood, 2018, 〈10.1182/blood-2018-03-841262〉, Blood, 2018, 131 (25), pp.2856-2859. ⟨10.1182/blood-2018-03-841262⟩
- Publication Year :
- 2018
- Publisher :
- HAL CCSD, 2018.
-
Abstract
- To the editor: Anti-programmed cell death protein 1 (anti-PD-1) antibodies demonstrated remarkable efficacy in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). In the 2 largest prospective studies that evaluated the anti-PD-1 antibodies nivolumab (CHECKMATE-205)[1][1] and
- Subjects :
- Adult
Male
0301 basic medicine
medicine.medical_specialty
Programmed Cell Death 1 Receptor
Immunology
[SDV.CAN]Life Sciences [q-bio]/Cancer
Biochemistry
Gastroenterology
[ SDV.CAN ] Life Sciences [q-bio]/Cancer
Cohort Studies
Young Adult
03 medical and health sciences
Antineoplastic Agents, Immunological
0302 clinical medicine
Refractory
Internal medicine
medicine
Humans
Young adult
Prospective cohort study
ComputingMilieux_MISCELLANEOUS
Aged
biology
business.industry
Remission Induction
Cell Biology
Hematology
Middle Aged
Hodgkin Disease
3. Good health
Discontinuation
Nivolumab
030104 developmental biology
030220 oncology & carcinogenesis
biology.protein
Hodgkin lymphoma
Female
Antibody
business
Cohort study
Subjects
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Database :
- OpenAIRE
- Journal :
- Blood, Blood, American Society of Hematology, 2018, 131 (25), pp.2856-2859. ⟨10.1182/blood-2018-03-841262⟩, Blood, 2018, 〈10.1182/blood-2018-03-841262〉, Blood, 2018, 131 (25), pp.2856-2859. ⟨10.1182/blood-2018-03-841262⟩
- Accession number :
- edsair.doi.dedup.....4bfd0355114f404c15b7a3bb705614c8
- Full Text :
- https://doi.org/10.1182/blood-2018-03-841262⟩